✦ LIBER ✦

Efficient inhibition of human B-cell lymphoma xenografts with an anti-CD20×anti-CD3 bispecific diabody

✍ Scribed by Dongsheng Xiong; Yuanfu Xu; Hanzhi Liu; Hui Peng; Xiaofeng Shao; Zenzu Lai; Dongmei Fan; Min Yang; Junling Han; Yong Xie; Chunzheng Yang; Zhenping Zhu

Book ID: 117467159
Publisher: Elsevier Science
Year: 2002
Tongue: English
Weight: 209 KB
Volume: 177
Category: Article
ISSN: 0304-3835
DOI: 10.1016/s0304-3835(01)00758-3

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Efficient inhibition of multidrug-resist

Efficient inhibition of multidrug-resistant human tumors with a recombinant bispecific anti-P-glycoprotein × anti-CD3 diabody

✍ Gao, Y; Xiong, D; Yang, M; Liu, H; Peng, H; Shao, X; Xu, Y; Xu, C; Fan, D; Qin, 📂 Article 📅 2004 🏛 Nature Publishing Group 🌐 English ⚖ 325 KB

Bi20 (fBTA05), a novel trifunctional bis

Bi20 (fBTA05), a novel trifunctional bispecific antibody (anti-CD20 × anti-CD3), mediates efficient killing of B-cell lymphoma cells even with very low CD20 expression levels

✍ Michael Stanglmaier; Margot Faltin; Peter Ruf; Annette Bodenhausen; Petra Schröd 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 French ⚖ 312 KB

## Abstract Trifunctional bispecific antibodies can efficiently mediate tumor cell killing by redirecting T cells and immune accessory cells to the tumor cell. Here, we describe the new trifunctional antibody, Bi20 (FBTA05, anti‐CD20 × anti‐CD3), that connects B cells and T cells __via__ its variab

In vitro Cytolysis of B-Lymphoma Cells M

In vitro Cytolysis of B-Lymphoma Cells Mediated by an Anti-CD3/Anti-CD20 Bispecific Single-chain Antibody

✍ YU, R; LI, S; WU, B; LIU, H; YE, L; LIU, X; WANG, Q; CHEN, Z 📂 Article 📅 2006 🏛 Elsevier Science ⚖ 872 KB

Efficient inhibition of B-cell lymphoma

Efficient inhibition of B-cell lymphoma xenografts with a novel recombinant fusion protein: anti-CD20Fab-LDM

✍ Xin, C; Ye, S; Ming, Y; Shenghua, Z; Qingfang, M; Hongxing, G; Xu, S; Yuanfu, X; 📂 Article 📅 2010 🏛 Nature Publishing Group 🌐 English ⚖ 646 KB

Phase I Clinical Trial Targeting CD20+ N

Phase I Clinical Trial Targeting CD20+ Non-Hodgkin'S Lymphoma (NHL) After Autologous Stem Cell Transplant With Anti-CD3 × Anti-CD20 Bispecific Antibody Armed T Cells

✍ L.G. Lum; A. Thakur; V. Ratanatharathorn; Z. Al-Kadhimi; E. Paul; C. Skuba; P. S 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 92 KB

T cells armed with anti-CD3 × anti-CD20

T cells armed with anti-CD3 × anti-CD20 bispecific antibody enhance killing of CD20+ malignant B cells and bypass complement-mediated rituximab resistance in vitro

✍ Jonathan M. Gall; Pamela A. Davol; Ryan C. Grabert; Mark Deaver; Lawrence G. Lum 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 317 KB